The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease

Neuron

Volumn 93, Issue 4, 2017, Pages 737-746

  Aflaki, Elma ^a   Westbroek, Wendy ^a   Sidransky, Ellen ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

alpha synuclein; autophagy; Gaucher disease; glucocerebrosidase; lysosome; parkinsonism

Indexed keywords

AFEGOSTAT; ALPHA SYNUCLEIN; AMBROXOL; GLUCOSYLCERAMIDASE; GLYCOSIDASE INHIBITOR; VENGLUSTAT;

AUTOPHAGOSOME; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ENZYME REPLACEMENT; GAUCHER DISEASE; GBA1 GENE; GENE; GENE MUTATION; GENETIC RISK; HUMAN; LYSOSOME; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; REVIEW; RISK FACTOR; ANIMAL; BRAIN; GENETICS; METABOLISM; MUTATION; PATHOLOGY; RARE DISEASE;

ANIMALS; BRAIN; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MUTATION; PARKINSONIAN DISORDERS; RARE DISEASES;

EID: 85013658130     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2017.01.018     Document Type: Review

References (98)

1. Aflaki, E., Stubblefield, B.K., Maniwang, E., Lopez, G., Moaven, N., Goldin, E., Marugan, J., Patnaik, S., Dutra, A., Southall, N., et al. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci. Transl. Med., 6, 2014, 240ra73.
2. Aflaki, E., Borger, D.K., Moaven, N., Stubblefield, B.K., Rogers, S.A., Patnaik, S., Schoenen, F.J., Westbroek, W., Zheng, W., Sullivan, P., et al. A new Glucocerebrosidase chaperone reduces α-Synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism. J. Neurosci. 36 (2016), 7441–7452.
3. Aharon-Peretz, J., Rosenbaum, H., Gershoni-Baruch, R., Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351 (2004), 1972–1977.
4. Alvarez-Erviti, L., Rodriguez-Oroz, M.C., Cooper, J.M., Caballero, C., Ferrer, I., Obeso, J.A., Schapira, A.H., Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 67 (2010), 1464–1472.
5. Awad, O., Sarkar, C., Panicker, L.M., Miller, D., Zeng, X., Sgambato, J.A., Lipinski, M.M., Feldman, R.A., Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum. Mol. Genet. 24 (2015), 5775–5788.
6. Beavan, M., McNeill, A., Proukakis, C., Hughes, D.A., Mehta, A., Schapira, A.H., Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol. 72 (2015), 201–208.
7. Berger-Sieczkowski, E., Lutz, M.I., Auff, E., Kovacs, G.G., Gaucher cells are not associated with α-synuclein neuropathology in infants. Clin. Neuropathol. 35 (2016), 122–128.
8. Beutler, E., Grabowski, G.A., Gaucher disease. Scriver, C.B.A., Beaudet, A.L., Sly, W.S., Valle, D., (eds.) The Metabolic & Molecular Bases of Inherited Disease, 2001, McGraw-Hill, 3635–3668.
9. Blanz, J., Saftig, P., Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J. Neurochem. 139:Suppl 1 (2016), 198–215.
10. Bobela, W., Aebischer, P., Schneider, B.L., Alpha-Synuclein as a mediator in the interplay between aging and Parkinson's disease. Biomolecules 5 (2015), 2675–2700.
11. Chetrit, E.B., Alcalay, R.N., Steiner-Birmanns, B., Altarescu, G., Phillips, M., Elstein, D., Zimran, A., Phenotype in patients with Gaucher disease and Parkinson disease. Blood Cells Mol. Dis. 50 (2013), 218–221.
12. Chu, Y., Kordower, J.H., Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?. Neurobiol. Dis. 25 (2007), 134–149.
13. Chu, Y., Dodiya, H., Aebischer, P., Olanow, C.W., Kordower, J.H., Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35 (2009), 385–398.
14. Cilia, R., Tunesi, S., Marotta, G., Cereda, E., Siri, C., Tesei, S., Zecchinelli, A.L., Canesi, M., Mariani, C.B., Meucci, N., et al. Survival and dementia in GBA-associated Parkinson's disease: the mutation matters. Ann. Neurol. 80 (2016), 662–673.
15. Cleeter, M.W., Chau, K.Y., Gluck, C., Mehta, A., Hughes, D.A., Duchen, M., Wood, N.W., Hardy, J., Mark Cooper, J., Schapira, A.H., Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem. Int. 62 (2013), 1–7.
16. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., Sulzer, D., Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 (2004), 1292–1295.
17. Cullen, V., Sardi, S.P., Ng, J., Xu, Y.H., Sun, Y., Tomlinson, J.J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69 (2011), 940–953.
18. Dagan, E., Schlesinger, I., Ayoub, M., Mory, A., Nassar, M., Kurolap, A., Peretz-Aharon, J., Gershoni-Baruch, R., The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat. Disord. 21 (2015), 1067–1071.
19. Dagan, E., Schlesinger, I., Kurolap, A., Ayoub, M., Nassar, M., Peretz-Aharon, J., Gershoni-Baruch, R., LRRK2, GBA and SMPD1 founder mutations and Parkinson's disease in Ashkenazi Jews. Dement. Geriatr. Cogn. Disord. 42 (2016), 1–6.
20. Davis, M.Y., Johnson, C.O., Leverenz, J.B., Weintraub, D., Trojanowski, J.Q., Chen-Plotkin, A., Van Deerlin, V.M., Quinn, J.F., Chung, K.A., Peterson-Hiller, A.L., et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurol. 73 (2016), 1217–1224.
21. Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., Björklund, A., TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl. Acad. Sci. USA 110 (2013), E1817–E1826.
22. Dermentzaki, G., Dimitriou, E., Xilouri, M., Michelakakis, H., Stefanis, L., Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells. PLoS ONE, 8, 2013, e60674.
23. Fernandes, H.J., Hartfield, E.M., Christian, H.C., Emmanoulidou, E., Zheng, Y., Booth, H., Bogetofte, H., Lang, C., Ryan, B.J., Sardi, S.P., et al. ER stress and autophagic perturbations lead to elevated extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-derived dopamine neurons. Stem Cell Reports 6 (2016), 342–356.
24. Gan-Or, Z., Amshalom, I., Kilarski, L.L., Bar-Shira, A., Gana-Weisz, M., Mirelman, A., Marder, K., Bressman, S., Giladi, N., Orr-Urtreger, A., Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 84 (2015), 880–887.
25. Ganat, Y.M., Calder, E.L., Kriks, S., Nelander, J., Tu, E.Y., Jia, F., Battista, D., Harrison, N., Parmar, M., Tomishima, M.J., et al. Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. J. Clin. Invest. 122 (2012), 2928–2939.
26. Gegg, M.E., Burke, D., Heales, S.J., Cooper, J.M., Hardy, J., Wood, N.W., Schapira, A.H., Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72 (2012), 455–463.
27. Goker-Alpan, O., Schiffmann, R., LaMarca, M.E., Nussbaum, R.L., McInerney-Leo, A., Sidransky, E., Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41 (2004), 937–940.
28. Goker-Alpan, O., Lopez, G., Vithayathil, J., Davis, J., Hallett, M., Sidransky, E., The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch. Neurol. 65 (2008), 1353–1357.
29. Goker-Alpan, O., Masdeu, J.C., Kohn, P.D., Ianni, A., Lopez, G., Groden, C., Chapman, M.C., Cropp, B., Eisenberg, D.P., Maniwang, E.D., et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 135 (2012), 2440–2448.
30. Goldin, E., Zheng, W., Motabar, O., Southall, N., Choi, J.H., Marugan, J., Austin, C.P., Sidransky, E., High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS ONE, 7, 2012, e29861.
31. Gonzalez, A., Valeiras, M., Sidransky, E., Tayebi, N., Lysosomal integral membrane protein-2: a new player in lysosome-related pathology. Mol. Genet. Metab. 111 (2014), 84–91.
32. Gramlich, P.A., Westbroek, W., Feldman, R.A., Awad, O., Mello, N., Remington, M.P., Sun, Y., Zhang, W., Sidransky, E., Betenbaugh, M.J., Fishman, P.S., A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: Design, production, and assessment. J. Biotechnol. 221 (2016), 1–12.
33. Gruschus, J.M., Jiang, Z., Yap, T.L., Hill, S.A., Grishaev, A., Piszczek, G., Sidransky, E., Lee, J.C., Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C. Biochem. Biophys. Res. Commun. 457 (2015), 561–566.
34. Hall, J., Prabhakar, S., Balaj, L., Lai, C.P., Cerione, R.A., Breakefield, X.O., Delivery of therapeutic proteins via extracellular vesicles: review and potential treatments for Parkinson's disease, Glioma, and Schwannoma. Cell. Mol. Neurobiol. 36 (2016), 417–427.
35. Horowitz, M., Elstein, D., Zimran, A., Goker-Alpan, O., New directions in Gaucher disease. Hum. Mutat. 37 (2016), 1121–1136.
36. Jung, O., Patnaik, S., Marugan, J., Sidransky, E., Westbroek, W., Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Rev. Proteomics 13 (2016), 471–479.
37. Khanna, R., Benjamin, E.R., Pellegrino, L., Schilling, A., Rigat, B.A., Soska, R., Nafar, H., Ranes, B.E., Feng, J., Lun, Y., et al. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J. 277 (2010), 1618–1638.
38. Korkotian, E., Segal, M., Release of calcium from stores alters the morphology of dendritic spines in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 96 (1999), 12068–12072.
39. Liu, G., Boot, B., Locascio, J.J., Jansen, I.E., Winder-Rhodes, S., Eberly, S., Elbaz, A., Brice, A., Ravina, B., van Hilten, J.J., et al., International Genetics of Parkinson Disease Progression (IGPP) Consortium. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Ann. Neurol. 80 (2016), 674–685.
40. Lopes da Fonseca, T., Villar-Piqué, A., Outeiro, T.F., The interplay between Alpha-Synuclein clearance and spreading. Biomolecules 5 (2015), 435–471.
41. Lopez, G., Kim, J., Wiggs, E., Cintron, D., Groden, C., Tayebi, N., Mistry, P.K., Pastores, G.M., Zimran, A., Goker-Alpan, O., Sidransky, E., Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurol Genet, 2, 2016, e57.
42. Luan, Z., Li, L., Higaki, K., Nanba, E., Suzuki, Y., Ohno, K., The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev. 35 (2013), 317–322.
43. Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M.E., Sidransky, E., Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81 (2004), 70–73.
44. Maegawa, G.H., Tropak, M.B., Buttner, J.D., Rigat, B.A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G.J., Hamuro, Y., Clarke, J.T., Mahuran, D.J., Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284 (2009), 23502–23516.
45. Mallett, V., Ross, J.P., Alcalay, R.N., Ambalavanan, A., Sidransky, E., Dion, P.A., Rouleau, G.A., Gan-Or, Z., GBA p.T369M substitution in Parkinson disease: polymorphism or association? A meta-analysis. Neurol Genet, 2, 2016, e104.
46. Maniwang, E., Tayebi, N., Sidransky, E., Is Parkinson disease associated with lysosomal integral membrane protein type-2?: challenges in interpreting association data. Mol. Genet. Metab. 108 (2013), 269–271.
47. Manning-Boğ, A.B., Schüle, B., Langston, J.W., Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30 (2009), 1127–1132.
48. Mao, C.Y., Yang, J., Wang, H., Zhang, S.Y., Yang, Z.H., Luo, H.Y., Li, F., Shi, M., Liu, Y.T., Zhuang, Z.P., et al. SMPD1 variants in Chinese Han patients with sporadic Parkinson's disease. Parkinsonism Relat. Disord. 34 (2016), 59–61.
49. Maor, G., Rencus-Lazar, S., Filocamo, M., Steller, H., Segal, D., Horowitz, M., Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J. Rare Dis., 8, 2013, 140.
50. Maor, G., Cabasso, O., Krivoruk, O., Rodriguez, J., Steller, H., Segal, D., Horowitz, M., The contribution of mutant GBA to the development of Parkinson disease in Drosophila. Hum. Mol. Genet. 25 (2016), 2712–2727.
51. Marshall, M.S., Bongarzone, E.R., Beyond Krabbe's disease: the potential contribution of galactosylceramidase deficiency to neuronal vulnerability in late-onset synucleinopathies. J. Neurosci. Res. 94 (2016), 1328–1332.
52. Marshall, J., Sun, Y., Bangari, D.S., Budman, E., Park, H., Nietupski, J.B., Allaire, A., Cromwell, M.A., Wang, B., Grabowski, G.A., et al. CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Mol. Ther. 24 (2016), 1019–1029.
53. Mata, I.F., Leverenz, J.B., Weintraub, D., Trojanowski, J.Q., Chen-Plotkin, A., Van Deerlin, V.M., Ritz, B., Rausch, R., Factor, S.A., Wood-Siverio, C., et al. GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov. Disord. 31 (2016), 95–102.
54. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A., Krainc, D., Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 (2011), 37–52.
55. Mazzulli, J.R., Zunke, F., Isacson, O., Studer, L., Krainc, D., α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc. Natl. Acad. Sci. USA 113 (2016), 1931–1936.
56. Mazzulli, J.R., Zunke, F., Tsunemi, T., Toker, N.J., Jeon, S., Burbulla, L.F., Patnaik, S., Sidransky, E., Marugan, J.J., Sue, C.M., Krainc, D., Activation of β-Glucocerebrosidase reduces pathological α-Synuclein and restores lysosomal function in Parkinson's patient midbrain neurons. J. Neurosci. 36 (2016), 7693–7706.
57. McGlinchey, R.P., Lee, J.C., Cysteine cathepsins are essential in lysosomal degradation of α-synuclein. Proc. Natl. Acad. Sci. USA 112 (2015), 9322–9327.
58. McNeill, A., Magalhaes, J., Shen, C., Chau, K.Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J.M., Abramov, A.Y., Gegg, M., Schapira, A.H., Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137 (2014), 1481–1495.
59. Michelakakis, H., Xiromerisiou, G., Dardiotis, E., Bozi, M., Vassilatis, D., Kountra, P.M., Patramani, G., Moraitou, M., Papadimitriou, D., Stamboulis, E., et al. Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease. Mov. Disord. 27 (2012), 400–405.
60. Murphy, K.E., Gysbers, A.M., Abbott, S.K., Tayebi, N., Kim, W.S., Sidransky, E., Cooper, A., Garner, B., Halliday, G.M., Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 137 (2014), 834–848.
61. Nalls, M.A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I.G., Chinnery, P.F., Morris, C.M., Theuns, J., Crosiers, D., Cras, P., et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70 (2013), 727–735.
62. Narita, A., Shirai, K., Itamura, S., Matsuda, A., Ishihara, A., Matsushita, K., Fukuda, C., Kubota, N., Takayama, R., Shigematsu, H., et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. Ann. Clin. Transl. Neurol. 3 (2016), 200–215.
63. Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., Zimran, A., Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89 (1996), 691–694.
64. Patnaik, S., Zheng, W., Choi, J.H., Motabar, O., Southall, N., Westbroek, W., Lea, W.A., Velayati, A., Goldin, E., Sidransky, E., et al. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med. Chem. 55 (2012), 5734–5748.
65. Pelled, D., Trajkovic-Bodennec, S., Lloyd-Evans, E., Sidransky, E., Schiffmann, R., Futerman, A.H., Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol. Dis. 18 (2005), 83–88.
66. Pfefferkorn, C.M., Jiang, Z., Lee, J.C., Biophysics of α-synuclein membrane interactions. Biochim. Biophys. Acta 1818 (2012), 162–171.
67. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
68. Roberts, H.L., Brown, D.R., Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules 5 (2015), 282–305.
69. Rocha, E.M., Smith, G.A., Park, E., Cao, H., Brown, E., Hallett, P., Isacson, O., Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann. Clin. Transl. Neurol. 2 (2015), 433–438.
70. Rockenstein, E., Clarke, J., Viel, C., Panarello, N., Treleaven, C.M., Kim, C., Spencer, B., Adame, A., Park, H., Dodge, J.C., et al. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease. Hum. Mol. Genet. 25 (2016), 2645–2660.
71. Rosenbloom, B., Balwani, M., Bronstein, J.M., Kolodny, E., Sathe, S., Gwosdow, A.R., Taylor, J.S., Cole, J.A., Zimran, A., Weinreb, N.J., The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol. Dis. 46 (2011), 95–102.
72. Rothaug, M., Zunke, F., Mazzulli, J.R., Schweizer, M., Altmeppen, H., Lüllmann-Rauch, R., Kallemeijn, W.W., Gaspar, P., Aerts, J.M., Glatzel, M., et al. LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. Proc. Natl. Acad. Sci. USA 111 (2014), 15573–15578.
73. Sardi, S.P., Clarke, J., Viel, C., Chan, M., Tamsett, T.J., Treleaven, C.M., Bu, J., Sweet, L., Passini, M.A., Dodge, J.C., et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. USA 110 (2013), 3537–3542.
74. Sardi, S.P., Cheng, S.H., Shihabuddin, L.S., Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle. Prog. Neurobiol. 125 (2015), 47–62.
75. Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R.S., et al. A gene network regulating lysosomal biogenesis and function. Science 325 (2009), 473–477.
76. Schapira, A.H., Glucocerebrosidase and Parkinson disease: recent advances. Mol. Cell. Neurosci. 66:Pt A (2015), 37–42.
77. Schöndorf, D.C., Aureli, M., McAllister, F.E., Hindley, C.J., Mayer, F., Schmid, B., Sardi, S.P., Valsecchi, M., Hoffmann, S., Schwarz, L.K., et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun., 5, 2014, 4028.
78. Settembre, C., Ballabio, A., TFEB regulates autophagy: an integrated coordination of cellular degradation and recycling processes. Autophagy 7 (2011), 1379–1381.
79. Settembre, C., Zoncu, R., Medina, D.L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M.C., et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31 (2012), 1095–1108.
80. Settembre, C., De Cegli, R., Mansueto, G., Saha, P.K., Vetrini, F., Visvikis, O., Huynh, T., Carissimo, A., Palmer, D., Klisch, T.J., et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat. Cell Biol. 15 (2013), 647–658.
81. Shachar, T., Lo Bianco, C., Recchia, A., Wiessner, C., Raas-Rothschild, A., Futerman, A.H., Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 26 (2011), 1593–1604.
82. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361 (2009), 1651–1661.
83. Siebert, M., Sidransky, E., Westbroek, W., Glucocerebrosidase is shaking up the synucleinopathies. Brain 137 (2014), 1304–1322.
84. Singleton, A., Hardy, J., The evolution of genetics: Alzheimer's and Parkinson's diseases. Neuron 90 (2016), 1154–1163.
85. Snead, D., Eliezer, D., Alpha-synuclein function and dysfunction on cellular membranes. Exp. Neurobiol. 23 (2014), 292–313.
86. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
87. Sun, Y., Liou, B., Xu, Y.H., Quinn, B., Zhang, W., Hamler, R., Setchell, K.D., Grabowski, G.A., Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J. Biol. Chem. 287 (2012), 4275–4287.
88. Tayebi, N., Callahan, M., Madike, V., Stubblefield, B.K., Orvisky, E., Krasnewich, D., Fillano, J.J., Sidransky, E., Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 73 (2001), 313–321.
89. Van Rossum, A., Holsopple, M., Enzyme replacement or substrate reduction? A review of Gaucher disease treatment options. Hosp. Pharm. 51 (2016), 553–563.
90. Visanji, N.P., Wislet-Gendebien, S., Oschipok, L.W., Zhang, G., Aubert, I., Fraser, P.E., Tandon, A., Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. J. Biol. Chem. 286 (2011), 35863–35873.
91. Weiss, K., Gonzalez, A.N., Lopez, G., Pedoeim, L., Groden, C., Sidransky, E., The clinical management of Type 2 Gaucher disease. Mol. Genet. Metab. 114 (2015), 110–122.
92. Wong, Y.C., Krainc, D., Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Mov. Disord. 31 (2016), 1610–1618.
93. Woodard, C.M., Campos, B.A., Kuo, S.H., Nirenberg, M.J., Nestor, M.W., Zimmer, M., Mosharov, E.V., Sulzer, D., Zhou, H., Paull, D., et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. Cell Rep. 9 (2014), 1173–1182.
94. Xin, W., Emadi, S., Williams, S., Liu, Q., Schulz, P., He, P., Alam, N.B., Wu, J., Sierks, M.R., Toxic oligomeric Alpha-Synuclein variants present in human Parkinson's disease brains are differentially generated in mammalian cell models. Biomolecules 5 (2015), 1634–1651.
95. Yap, T.L., Gruschus, J.M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., Lee, J.C., Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 286 (2011), 28080–28088.
96. Yap, T.L., Gruschus, J.M., Velayati, A., Sidransky, E., Lee, J.C., Saposin C protects glucocerebrosidase against α-synuclein inhibition. Biochemistry 52 (2013), 7161–7163.
97. Yap, T.L., Jiang, Z., Heinrich, F., Gruschus, J.M., Pfefferkorn, C.M., Barros, M., Curtis, J.E., Sidransky, E., Lee, J.C., Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy. J. Biol. Chem. 290 (2015), 744–754.
98. Zimran, A., Altarescu, G., Elstein, D., Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis. 50 (2013), 134–137.